Longevity
Altos Labs and the $3 Billion Bet on Reversing Cellular Aging
The best-funded biotech launch in history is chasing a way to rewind aging inside cells. The lab data is striking, the human proof is not yet there.
// Longevity
Longevity
The science of healthspan: cellular reprogramming, drugs, biomarkers and aging research.
Longevity
Epigenetic Clocks and the Biological-Age Boom
DNA-methylation tests promise to reveal how fast you are really aging. Here is what the major clocks measure, what the kits cost, and why researchers say to read the numbers carefully.
Longevity
The Longevity Drug Pipeline: What Rapamycin, Metformin and Senolytics Can Actually Do
Three classes of drug dominate the anti-aging conversation. Here is what each one does, what the trials actually show, and why none is approved to extend human life.
Longevity
NAD+ Supplements: What the Science Actually Shows
NMN and NR reliably raise a key cellular molecule. Whether that slows aging in people is still an open question.
Longevity
Inside Biograph: The $7,500 Longevity Clinic
Peter Attia's diagnostics startup sells a one-day, whole-body health workup to the wealthy. Here is what it costs, what it scans, and why doctors are split on the model.